Press release

ThromboGenics Presenting Industry Expertise and Developments at Bio€quity Europe and Knowledge for Growth meetings in Ghent, Belgium

Leuven, Belgium, 14 May 2018 – ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that it will be presenting at Bio€quity Europe taking place from 14-16 May, 2018 and at Knowledge for Growth, which takes place on 17 May, 2018. Both events are being held in Ghent, Belgium.

At Bio€quity Europe, CEO Patrik De Haes, MD will be providing an update on progress and outlook with regards to the Company's strategy and its industry-leading diabetic eye disease development pipeline.

Separately, at the Knowledge for Growth meeting later in the week, CSO Jean Feyen, PhD, will present his insights on the industry development pipeline for diabetic eye disease.

Details of the presentations are as follows:

Bio€quity Europe
Date: Tuesday 15 May 2018
Time: 17:00 CEST
Location: Level 1+, Priorzaal, Het Pand, Ghent University

Knowledge for Growth
Date: Thursday 17 May 2018
Time: 11:35 CEST
Location: Jan van Eyck Room (1st Floor), International Convention Center Ghent

Bio€quity Europe is a life science focused investor and partnering event organised by BioCentury, now celebrating its 19th annual meeting. It has showcased more than 700 leading European companies to thousands of investment and pharma business development professionals.

Knowledge for Growth is a European life sciences conference organised by flanders.bio, providing insight into the global life sciences' landscape, B2B Partnering, a trade fair with 100+ exhibitors and scientific poster presentations.

For further information please contact:

ThromboGenics Wouter Piepers, Global Head of Corp Coms & Investor Relations +32 16 75 13 10 / +32 478 33 56 32 wouter.piepers@thrombogenics.com	**Citigate Dewe Rogerson** David Dible/Sylvie Berrebi/Isabelle Andrews Tel: +44 20 7282 2867 thrombogenics@citigatedewerogerson.com

ThromboGenics®
Advancing Science. Enhancing Vision.®

About ThromboGenics

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.

ThromboGenics' is developing THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema, which is in an ongoing Phase 2 clinical study in combination with ranibizumab (Lucentis®, Novartis). ThromboGenics' late pre-clinical pipeline consists of THR-149, a plasma kallikrein inhibitor, and THR-687, an integrin antagonist. THR-149 is targeted to enter the clinic in H1 2018 and THR-687 around mid-2018. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.

ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US).

ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.